AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus strengthens its global leadership team with accomplished leaders- appoints Silke Otte as Chief Marketing Officer and Graeme Mcfarlane as the Chief Commercial Officer
Innoplexus AG, a leading AI based analytics as a service provider in life sciences and financial services domain, announced today appointment of Lawrence Ganti as Chief Executive Officer of Innoplexus, Americas, further strengthening its leadership team.
Lawrence is widely respected as exceptional team builder and accomplished leader in Pharma Industry. His addition to leadership team will play crucial role in our company’s transformational journey”, said Dr. Gunjan Bhardwaj, Global CEO, Innoplexus.
Lawrence brings over 20 years of experience in healthcare, technology, and consumer goods where he has worked across general management, commercial development, strategy formulation, and marketing. Amongst his many achievements, Lawrence led the post merger integration of Merck and Serono’s international business; implemented a turnaround of Merck’s business in India; spearheaded a transformation of the Latin America operations; and launched an award winning marketing campaign in Japan.
Prior to joining Innoplexus, he built an impressive career over 14 years with Merck KGaA, where he held various leadership positions across Europe, Asia, and Latin America. Most recently Lawrence held the position of President – Latin America at Merck. He started his career with PepsiCo, Marriott, and Johnson & Johnson, then moved to McKinsey & Company before taking on business development roles for various technology startups. Lawrence holds an MBA from IMD In Switzerland and BS in Entrepreneurship from Babson College, USA. He will be based out of New Jersey, USA.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…